DK1047416T3 - Farmaceutiske præparater der omfatter disulfiram til inhibering af angionese - Google Patents

Farmaceutiske præparater der omfatter disulfiram til inhibering af angionese

Info

Publication number
DK1047416T3
DK1047416T3 DK99900280T DK99900280T DK1047416T3 DK 1047416 T3 DK1047416 T3 DK 1047416T3 DK 99900280 T DK99900280 T DK 99900280T DK 99900280 T DK99900280 T DK 99900280T DK 1047416 T3 DK1047416 T3 DK 1047416T3
Authority
DK
Denmark
Prior art keywords
disulfiram
angionesis
inhibiting
pharmaceutical compositions
angiogenesis
Prior art date
Application number
DK99900280T
Other languages
Danish (da)
English (en)
Inventor
Moshe Marikovsky
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK1047416T3 publication Critical patent/DK1047416T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
DK99900280T 1998-01-11 1999-01-11 Farmaceutiske præparater der omfatter disulfiram til inhibering af angionese DK1047416T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12289298A IL122892A0 (en) 1998-01-11 1998-01-11 Pharmaceutical compositions comprising a thiocarbamate
PCT/IL1999/000017 WO1999034784A2 (en) 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
DK1047416T3 true DK1047416T3 (da) 2008-11-17

Family

ID=11071076

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99900280T DK1047416T3 (da) 1998-01-11 1999-01-11 Farmaceutiske præparater der omfatter disulfiram til inhibering af angionese

Country Status (9)

Country Link
US (1) US6288110B1 (enExample)
EP (1) EP1047416B1 (enExample)
JP (1) JP2002500180A (enExample)
AT (1) ATE401879T1 (enExample)
AU (1) AU1888599A (enExample)
DE (1) DE69939155D1 (enExample)
DK (1) DK1047416T3 (enExample)
IL (1) IL122892A0 (enExample)
WO (1) WO1999034784A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589987B2 (en) 1998-09-08 2003-07-08 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using tetraethyl thiuram disulfide
US6706759B1 (en) 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US6548540B2 (en) * 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
AU2002226650A1 (en) * 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
US20040157837A1 (en) * 2002-11-07 2004-08-12 Serbedzija George N. Combinations for the treatment of fungal infections
WO2007065167A1 (en) * 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008068746A2 (en) * 2006-12-04 2008-06-12 Yeda Research And Development Co. Ltd. Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
EP2632450A1 (en) * 2010-08-31 2013-09-04 Avidal Vascular GmbH Compositions comprising a taxane for coating medical devices
JP6206939B2 (ja) * 2011-10-11 2017-10-04 国立大学法人 千葉大学 肝がん幹細胞阻害剤
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2015120254A1 (en) * 2014-02-06 2015-08-13 Texas Tech University System Disulfiram compositions and treatments for brain tumors
GB201407806D0 (en) 2014-05-02 2014-06-18 Ucl Business Plc Treatment of fibrosis
GB201519643D0 (en) * 2015-11-06 2015-12-23 Univ Wolverhampton Disulfiram formulation
WO2017177947A1 (zh) 2016-04-13 2017-10-19 诺马（北京）科技有限公司 局部注射双硫仑制剂治疗胸腹膜癌症的方法
EP3311843A1 (en) 2016-10-13 2018-04-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Compositions comprising dithiocarbamate and cyclodextrin
US11298396B2 (en) 2017-03-17 2022-04-12 Osaka University Agent for inhibiting or reducing light sensitivity
EP3813805A4 (en) * 2018-06-27 2021-08-25 Children's Medical Center Corporation INFLAMMATION INHIBITION COMPOUNDS
US11311538B2 (en) 2018-07-13 2022-04-26 Yale University Compositions and methods for targeting cancers
EP3693740A1 (en) 2019-02-07 2020-08-12 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved dithiocarmabate based compounds, therapies and diagnostics
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
EP4135660A1 (en) * 2020-04-16 2023-02-22 Atossa Therapeutics, Inc. Compositions and methods to reduce the infectivity of a virus
WO2021231814A1 (en) * 2020-05-14 2021-11-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
US12070468B2 (en) * 2020-05-14 2024-08-27 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
WO2022061171A1 (en) * 2020-09-18 2022-03-24 Spring Discovery, Inc. Combination therapies with disulfiram
US11065214B1 (en) * 2020-09-18 2021-07-20 Spring Discovery, Inc. Combination therapies with disulfiram
CN114376997B (zh) * 2021-10-10 2023-04-28 深圳市人民医院 一种新型IRE1a抑制剂紫草素及与双硫仑协同抗肿瘤组合方式

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284879A3 (en) * 1987-03-17 1990-10-17 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US4870101A (en) * 1987-03-17 1989-09-26 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

Also Published As

Publication number Publication date
WO1999034784A2 (en) 1999-07-15
IL122892A0 (en) 1998-08-16
WO1999034784A3 (en) 2000-09-08
EP1047416B1 (en) 2008-07-23
DE69939155D1 (de) 2008-09-04
EP1047416A2 (en) 2000-11-02
AU1888599A (en) 1999-07-26
ATE401879T1 (de) 2008-08-15
JP2002500180A (ja) 2002-01-08
US6288110B1 (en) 2001-09-11

Similar Documents

Publication Publication Date Title
ATE401879T1 (de) Disulfiram enthaltende arzneimittel
DE60137966D1 (de) Anilinopyrimidin derivate als "jnk pathway inhibitoren", zusammensetzungen und damit verbundene behandlungsmethoden
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE216879T1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE60019195D1 (de) Behandlung durch Ablation von Knochenmetastasen
DE59910682D1 (de) Verwendung von Flavonen, Flavanonen bzw. Flavonoiden zum Schutze von Ascorbinsäure und/oder Ascorbylverbindungen gegen Oxidation
NO305537B1 (no) Farmas°ytisk preparat inneholdene et definert lipidsystem, og anvendelse av lipidsystemet
DE69837295D1 (de) Probucolbernsteinsäureester zur Hemmung der Expression von VCAM-1
ATE300597T1 (de) Behandlung von geweben
ATE212351T1 (de) Androsten-derivate
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
NZ513096A (en) Compositions for treating inflammatory response
ATE255894T1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
DE69713300D1 (de) Benzopyran derivate mit leukotrien-antagonistischer wirkung
DK71387D0 (da) Terapeutisk middel til behandling af psoriasis
PL357674A1 (pl) Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią
ATE469907T1 (de) Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
DE60002226D1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l-carnitin derivate und ginkgo biloba extrakte
SE9902267D0 (sv) New compounds
ATE381327T1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
NO20014240D0 (no) C16-umettede FP-selektive prostaglandinanaloger
DE3684213D1 (de) Tri-nickel-aluminid-zuammensetzungen und ihre behandlung zur erhoehung der widerstandsfaehigkeit.
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
DE69924979D1 (de) Behandlung von chronischen schmerzen